<?xml version='1.0' encoding='utf-8'?>
<document id="26189431"><sentence text="Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid."><entity charOffset="76-86" id="DDI-PubMed.26189431.s1.e0" text="atazanavir" /><entity charOffset="90-100" id="DDI-PubMed.26189431.s1.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.26189431.s1.e0" e2="DDI-PubMed.26189431.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26189431.s1.e0" e2="DDI-PubMed.26189431.s1.e1" /></sentence><sentence text="Pradigastat, a novel diacylglycerol acyltransferase-1 inhibitor, has activity in common metabolic diseases associated with abnormal accumulation of triglycerides"><entity charOffset="21-35" id="DDI-PubMed.26189431.s2.e0" text="diacylglycerol" /><entity charOffset="148-161" id="DDI-PubMed.26189431.s2.e1" text="triglycerides" /><pair ddi="false" e1="DDI-PubMed.26189431.s2.e0" e2="DDI-PubMed.26189431.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26189431.s2.e0" e2="DDI-PubMed.26189431.s2.e1" /></sentence><sentence text=" In vitro studies suggest that glucuronidation is the predominant metabolism pathway for elimination of pradigastat in humans and confirmed the role of uridine 5'-diphosphoglucuronosyltransferase (UGT) enzymes, UGT1A1, -1A3, and -2B7"><entity charOffset="152-159" id="DDI-PubMed.26189431.s3.e0" text="uridine" /></sentence><sentence text=" The in vitro studies using atazanavir as a selective inhibitor of UGT1A1 and -1A3 indicated that these enzymes contribute ∼55% toward the overall glucuronidation pathway"><entity charOffset="28-38" id="DDI-PubMed.26189431.s4.e0" text="atazanavir" /></sentence><sentence text=" Therefore, a clinical study was conducted to assess the potential for drug interaction between pradigastat and probenecid (purported general UGT inhibitor) or atazanavir (selective UGT1A1, -1A3 inhibitor)"><entity charOffset="160-170" id="DDI-PubMed.26189431.s5.e0" text="atazanavir" /></sentence><sentence text=" The study included 2 parallel cohorts, each with 3 sequential treatment periods and 22 healthy subjects per cohort" /><sentence text=" The 90%CI of the geometric mean ratios for Cmax,ss and AUCτ,ss of pradigastat were within 0" /><sentence text="80-1" /><sentence text="25 when administered in combination with probenecid"><entity charOffset="41-51" id="DDI-PubMed.26189431.s9.e0" text="probenecid" /></sentence><sentence text=" However, the Cmax,ss and AUCτ,ss of pradigastat decreased by 31% (90%CI: 0" /><sentence text="62-0" /><sentence text="78) and 26% (0" /><sentence text="67-0" /><sentence text="82), respectively, when administered in combination with atazanavir"><entity charOffset="57-67" id="DDI-PubMed.26189431.s14.e0" text="atazanavir" /></sentence><sentence text=" This magnitude of decrease in pradigastat steady-state exposure is not considered clinically relevant" /><sentence text=" Pradigastat was well tolerated by all subjects, either alone or in combination with atazanavir or probenecid"><entity charOffset="85-95" id="DDI-PubMed.26189431.s16.e0" text="atazanavir" /><entity charOffset="99-109" id="DDI-PubMed.26189431.s16.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.26189431.s16.e0" e2="DDI-PubMed.26189431.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26189431.s16.e0" e2="DDI-PubMed.26189431.s16.e1" /></sentence><sentence text=" " /></document>